Predina JD, et al. - In an open-label feasibility trial including 25 subjects with anterior mediastinal lesions suspicious for malignancy, researchers tested intraoperative near-infrared (NIR) imaging as an approach to improving tumor delineation during mediastinal tumor resection. They administered indocyanine green (ICG) to participants at a dose of 5 mg/kg, 24 hours before resection (via a technique called TumorGlow). The Artemis (Quest, Middenmeer, the Netherlands) and Iridium (VisionSense Corp, Philadelphia, Pennsylvania) were used as the NIR imaging systems. They assessed intratumoral ICG uptake as well as clinical value by evaluating the ability of NIR imaging to detect phrenic nerve involvement or incomplete resection. Findings demonstrated safety and feasibility of NIR imaging for anterior mediastinal neoplasms, with no drug-related toxicity detected. Via NIR feedback, improvement was seen in phrenic nerve dissection and detection of residual disease was possible. No false-positives or false-negatives were reported. NIR imaging could afford a real-time tool capable of determining tumor extent.